KLK3 and prostate carcinoma: Thirty years after the U.S. Food and Drug Administration (FDA) approved serum prostate-specific antigen (PSA) testing for the early detection of prostate cancer (PCa) [1,2], the European Union (EU) recommended screening for PCa.